Panelists discuss how an 18-month retrospective claims analysis evaluated ruxolitinib's real-world effectiveness in atopic ...

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and ...

Republicans are aiming for major reductions in federal spending, and Medicaid seems a likely target. But the politics of ...

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

The end of federal diversity, equity and inclusion programs in the federal government may have a ripple effect on social ...

One particular application of AI on the rise at City of Hope is the development of a large language model (LLM) made ...

United Health Foundation, the charitable branch of UnitedHealth Group, awarded more than $7 million in grants to ...

The CEOs of CVS Health and UnitedHealth Group praised pharmacy benefit managers and promised transparency during investor ...

Lexeo Therapeutics’ gene therapy provides a healthy version of the frataxin gene, which is critical for energy production in ...

A new article argues dystrophin immunogenicity is an under-examined issue in the treatment of Duchenne muscular dystrophy.

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...